Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Accredo Therapeutics, a division of Accredo Health, has been selected as a specialty pharmacy provider for CoTherix' pulmonary arterial hypertension treatment, Ventavis.
Subscribe to our email newsletter
Ventavis (iloprost) was recently approved by the FDA for the treatment of pulmonary arterial hypertension (PAH) in patients with New York Heart Association class III or IV symptoms. Ventavis is an inhaled formulation of iloprost, a synthetic compound structurally similar to naturally occurring molecules that cause blood vessels to dilate.
Accredo, with its 38 branch pharmacies nationwide, will exclusively provide call center and reimbursement support services for patients using Ventavis and their prescribing physicians and support staff.
“With the addition of this product, we continue our strong commitment to the PAH patient and physician community by offering another alternative to the treatment of this condition,” stated David Stevens, Accredo’s chairman and CEO.
Accredo Health provides specialized pharmacy and related services pursuant to agreements with biotechnology drug manufacturers, relating to the treatment of patients with certain costly, chronic diseases.